COMT and prostate carcinoma: This property is supported by the lower levels of COMT observed in prostate cancer compared to normal regions according to TCGA though a trend (p = 0.2; Fig 1A) but significantly compared to BPH in our clinical specimens (p = 0.004; Fig 1E).